# Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September Canonical URL: https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-septem-192a6967 Ticker: RLAY Company: Relay Therapeutics Source: Relay Therapeutics Published: 2025-08-28 20:05 EST ## Summary Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company... ## Article Body Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September: 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. ET Morgan Stanley 23rd Annual Global Conference on Wednesday, September 10, 2025 at 11:30 a.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations . An archived replay of the webcast will be available for up to 30 days following the event. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo ® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, RLY-2608, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. RLY-2608 is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular malformations. Relay's pipeline also includes late-stage research programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn . Contact: Pete Rahmer prahmer@relaytx.com Media: Dan Budwick 1AB 973-271-6085 dan@1abmedia.com ## Recent Company News - 2026-05-27 20:05 EST — [Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June](https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-june-9d492b03) — Source: Relay Therapeutics - 2026-05-21 00:21 EST — [Relay Therapeutics Announces Pricing of Public Offering of Common Stock](https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-pricing-of-public-offering-of-common-stock-00372d13) — Source: Relay Therapeutics - 2026-05-19 20:03 EST — [Relay Therapeutics Announces Proposed Public Offering of Common Stock](https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-proposed-public-offering-of-common-stock-858217e7) — Source: Relay Therapeutics - 2026-05-19 10:00 EST — [Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies](https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-initial-clinical-data-demonstrating-that-zovegalisi-7d0d964f) — Source: Relay Therapeutics - 2026-05-05 20:05 EST — [Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates](https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-first-quarter-2026-financial-results-and-corporate-up-9af87a5e) — Source: Relay Therapeutics ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)